首页> 外文期刊>Current medicinal chemistry. Anti-infective agents >Discovery, Structure-Activity Relationships and Unique Properties of Non-Fluorinated Quinolones (NFQs)
【24h】

Discovery, Structure-Activity Relationships and Unique Properties of Non-Fluorinated Quinolones (NFQs)

机译:非氟化喹诺酮类化合物的发现,构效关系和独特性质

获取原文
获取原文并翻译 | 示例
       

摘要

The use of antibacterial antibiotics in therapy represents a huge selection pressure for bacteria leading to increasing levels of resistance to these agents. A more controlled usage of these drugs may be a way to partially counterbalance this bacterial evolution. However, the design of new agents active against resistant organisms remains of critical importance. 6-Fluorinated quinolones, like Ciprofloxacin, represent a very significant improvement over the first generation quinolones (eg nalidixic acid) in terms of potency, spectrum and pharmacodynamic properties, Unfortunately, once introduced in clinic, these agents faced a rapid emergence of resistance from gram-positive organisms. The subsequent efforts to improve the fluoroquinolones' gram-positive spectrum were significantly hindered by the parallel existing between the fluoroquinolones' gram-positive potency and their genotoxicity Challenging the 6-fluorine dogma, it was found that by selecting the proper set of substituents at 1, 8 and 7 positions, broad-spectrum quinolones of very high gram-positive potency could be obtained The potential of this non-fluorinated series became clearer when two independent reports showed that non-fluorinated quinolones were consistently less genotoxic than their 6-fluorinated counterparts Additionally, the unique structure-activity relationships of 6-hydroquinolones and the finding of previously unreported resistance mutations induced by these agents are indications that these analogs may not interact with their target, the type II bacterial topoisomerases, in a way similar to typical fluoroquinolones. This set of unique properties makes the 6-hydroquinolones or Non-fluorinated Quinolones (NFQs) a very appealing platform from which new broad-spectrum agents with better potency against gram-positive pathogens can be identified.
机译:在治疗中使用抗菌抗生素代表了巨大的细菌选择压力,导致对这些药物的耐药性不断提高。这些药物的更受控使用可能是部分抵消这种细菌进化的一种方式。但是,设计具有抗性的新活性剂仍然至关重要。 6-氟喹诺酮类药物,如环丙沙星,在功效,谱图和药效学性质方面比第一代喹诺酮类药物(例如萘啶酸)有显着改善。不幸的是,一旦将其引入临床,这些药物就面临着革兰氏耐药性的快速出现阳性生物。后来由于氟喹诺酮类药物的革兰氏阳性药效与它们的遗传毒性之间的平行关系,显着阻碍了改进氟喹诺酮类药物的革兰氏阳性谱的研究,从而发现通过选择合适的一组取代基(在1处),存在挑战性。 ,8和7位,可以获得非常高的革兰氏阳性药效的广谱喹诺酮。当两个独立的报告显示,非氟化喹诺酮的遗传毒性始终低于6-氟喹诺酮时,这种非氟化喹诺酮的遗传毒性变得更明显。另外,6-氢喹诺酮类的独特的结构-活性关系以及由这些试剂诱导的先前未报道的抗性突变的发现表明这些类似物可能不会以类似于典型的氟喹诺酮类的方式与其靶标II型细菌拓扑异构酶相互作用。这组独特的性能使6-氢喹诺酮或非氟化喹诺酮(NFQ)成为一个非常吸引人的平台,从中可以鉴定出对革兰氏阳性病原体具有更好效力的新型广谱制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号